Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Sarcoma 1Gynecologic 1

Conditions

Sarcoma 6Pancreatic Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 5Sarcoma, Ewing 4Ovarian Neoplasms 4Breast Neoplasms 4Neoplasms 3Insulin-Like Growth Factor I, Resistance To 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Lymphoma 2Colonic Neoplasms 2Carcinoid Tumor 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pathologic Complete Response 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Trastuzumab 625Paclitaxel 576Cyclophosphamide 555Docetaxel 484Capecitabine 401Letrozole 376Fulvestrant 326Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 184Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Breast Neoplasms × ganitumab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00626106 2024-09-19

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

NantCell, Inc.

Phase 2 Completed
156 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Novartis

Phase 1/2 Terminated
47 enrolled 23 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01479179 2016-10-26

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡